Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
New Haven, Connecticut. August 5, 2008 — Rib-X Pharmaceuticals, Inc.,
a development stage company focused on the discovery and development of novel antibiotics
for the treatment of antibiotic-resistant infections, announced today that company representatives
are giving three presentations at two conferences this week.
Additionally, Graham Johnson, Ph.D, Chief Research Officer of Rib-X will give a presentation in the "Late-Breaking Topics" session, Thursday, August 7. The title of the talk is "Discovery and Clinical Development of radezolid (RX-1741), a Designer Oxazolidinone" and will highlight the Company's proprietary discovery process utilizing structural, computational and chemistry approaches; radezolid has distinct physical properties as well as a promising efficacy and safety profile.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community acquired and hospital acquired pathogens. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology, and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is an exciting discovery program that is well on its way toward the identification of new chemical classes of antibiotics active against multi-drug resistant Gram-negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci. Radezolid and the multiple discovery programs derive from Rib-X's proprietary use of the ribosome structure and computational tools.
Gordon Research Conference on Medicinal Chemistry, August 3 — 8
Ashoke Bhattacharjee, Ph.D, Senior Scientist, presented at the Gordon Research Conference on
Medicinal Chemistry this week at Colby Sawyer College, New London, New Hampshire. Dr. Bhattacharjee
introduced Rib-X's enhanced macrolide program in a poster session titled, "Structure Based Drug
Design Targeting Infectious Disease: Overcoming Resistance and Extending the Antimicrobial Spectrum
of Macrolide Antibiotics." In his presentation on August 3 and 4, Dr. Bhattacharjee
highlighted how the combination of structural insights from X-ray crystallographic studies of
known and new antibiotics bound to the bacterial 50S ribosomal subunit with data driven
computational chemistry tools allows for a fresh look at macrolide antibiotics.
Additionally, Graham Johnson, Ph.D, Chief Research Officer of Rib-X will give a presentation in the "Late-Breaking Topics" session, Thursday, August 7. The title of the talk is "Discovery and Clinical Development of radezolid (RX-1741), a Designer Oxazolidinone" and will highlight the Company's proprietary discovery process utilizing structural, computational and chemistry approaches; radezolid has distinct physical properties as well as a promising efficacy and safety profile.
Drug Discovery & Development of Innovative Therapeutics World Conference, August 4 — 7
Joseph DeVito, Ph.D, Associate Director, Discovery Biology, Rib-X Pharmaceuticals, Inc., is presenting
Rib-X's Rχ-04 program at IBC's 12th Annual Drug Discovery & Development of Innovative Therapeutics
World Conference Technology Conference today at 11:00 AM ET at The World Trade Center Boston and
Seaport Hotel, Boston, Massachusetts. Dr. DeVito will highlight RX-04 in a presentation titled "Using
Structure Based Discovery to Define Novel Antibiotics Targeting the 50S Ribosomal Subunit." Rχ-04
is Rib-X's
de novo
design of three completely new series of antibacterials showing promising activity against serious
multidrug resistant Gram-negative pathogens, including,
Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Klebsiella pneumoniae, Acinetobacter baumanii
and
Escherichia coli.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community acquired and hospital acquired pathogens. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology, and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is an exciting discovery program that is well on its way toward the identification of new chemical classes of antibiotics active against multi-drug resistant Gram-negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci. Radezolid and the multiple discovery programs derive from Rib-X's proprietary use of the ribosome structure and computational tools.
| Media/Investor Contact Information |
|---|
|
Gina Nugent
The Yates Network 617.460.3579 gina@theyatesnetwork.com |